WHAT IS CLAIMED:

1. An anti-human α4β7 antibody which comprises (i) a VH chain region comprising three CDRs; and (ii) a VL chain region comprising three CDRs, wherein:
   VH CDR#1 is GFNIKNTYMH (SEQ ID NO:72);
   VH CDR#2 is RIDPAKGHTEYAPKFLG (SEQ ID NO:73);
   VH CDR#3 is VDV (SEQ ID NO:74);
   VL CDR#1 is HASQDISDNIG (SEQ ID NO:75);
   VL CDR#2 is HGTNLED (SEQ ID NO:76); and
   VL CDR#3 is VQYAQFPWT (SEQ ID NO:77).

2. The anti-human α4β7 antibody of claim 1, which comprises
   a VH chain region of:
   EVQLVQSGAEVKKPGSSVKVSCKASGFNIKNTYMHWVRQAPGQGLEWIGRIDP
   AKGHTEYAPKFLGRVTITADESTNTAYMELSSLRSEDTAVYYCYYVDVWGQGT
   TVTVSS (SEQ ID NO:70); and
   a VL chain region of:
   DIQMTQSPSSLSASVGDRVTITCHASQDISDNIGWLQQKPGKSFKLLIYHGTNLED
   GVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKVEIK
   (SEQ ID NO:71).

3. The anti-human α4β7 antibody of claim 2, which is an IgG.

4. The anti-human α4β7 antibody of claim 3, comprising a kappa light constant region.

5. The anti-human α4β7 antibody of claim 4, which is an IgG_1.

6. The anti-human α4β7 antibody of claim 5, comprising a variant CH3 domain having amino acid substitutions D356E and L358M.

7. The anti-human α4β7 antibody of claim 1, which comprises a heavy chain having an amino acid sequence of SEQ ID NO:92 or SEQ ID NO:93, and a light chain having an amino acid sequence of SEQ ID NO:100.

8. The anti-human α4β7 antibody of claim 1, which is an IgG1 antibody comprising heavy chains each consisting of the amino acid sequence of SEQ ID NO:92, and light chains each consisting of the amino acid sequence of SEQ ID NO:100.

9. The anti-human α4β7 antibody of claim 1, which is an IgG1 antibody comprising heavy chains each consisting of the amino acid sequence of SEQ ID NO:93, and light chains each consisting of the amino acid sequence of SEQ ID NO:100.

10. A polynucleotide comprising a nucleotide sequence encoding an anti-human α4β7 antibody, wherein the antibody comprises (i) a VH chain region comprising three CDRs; and (ii) a VL chain region comprising three CDRs, wherein:

VH CDR#1 is GFNIKNTYMH (SEQ ID NO:72);
VH CDR#2 is RIDPAKGHTEYAPKFLG (SEQ ID NO:73);
VH CDR#3 is VDV (SEQ ID NO:74);
VL CDR#1 is HASQDISDNIG (SEQ ID NO:75);
VL CDR#2 is HGTNLED (SEQ ID NO:76); and
VL CDR#3 is VQYAQFPWT (SEQ ID NO:77).

11. An expression vector comprising the polynucleotide of claim 10.

12. A eukaryotic host cell transfected with the vector of claim 11.

13. The eukaryotic host cell of claim 12, which is a mammalian host cell.

14. A method of producing an anti-human α4β7 antibody, comprising: (a) culturing the eukaryotic host cell of claim 13 and (b) recovering the anti-human α4β7 antibody.

15. ~~A method of inducing viral suppression of HIV infection in an HIV-infected subject, comprising administering to the subject an amount~~ Use of the anti-human α4β7 antibody of any one of claims 1-9 in the manufacture of a medicament for inducing viral suppression of HIV infection in an HIV-infected subject.

16. ~~A method of treating HIV infection in an HIV-infected subject, comprising administering to the subject an amount~~ Use of the anti-human α4β7 antibody of any one of claims 1-9 in the manufacture of a medicament for treating HIV infection in an HIV-infected subject.

17. The anti-human α4β7 antibody of any one of claims 1-9 for use in therapy.

~~17~~18. A pharmaceutical composition comprising an antibody of any one of the claims 1-9.